Does RADIUM RA-223 DICHLORIDE Cause Hormone-refractory prostate cancer? 441 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 441 reports of Hormone-refractory prostate cancer have been filed in association with RADIUM RA-223 DICHLORIDE (Xofigo). This represents 9.2% of all adverse event reports for RADIUM RA-223 DICHLORIDE.
441
Reports of Hormone-refractory prostate cancer with RADIUM RA-223 DICHLORIDE
9.2%
of all RADIUM RA-223 DICHLORIDE reports
154
Deaths
66
Hospitalizations
How Dangerous Is Hormone-refractory prostate cancer From RADIUM RA-223 DICHLORIDE?
Of the 441 reports, 154 (34.9%) resulted in death, 66 (15.0%) required hospitalization, and 11 (2.5%) were considered life-threatening.
Is Hormone-refractory prostate cancer Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RADIUM RA-223 DICHLORIDE. However, 441 reports have been filed with the FAERS database.
What Other Side Effects Does RADIUM RA-223 DICHLORIDE Cause?
Prostatic specific antigen increased (449)
Death (376)
Anaemia (324)
Metastases to bone (315)
General physical health deterioration (308)
Fatigue (242)
Haemoglobin decreased (236)
Prostate cancer (234)
Nausea (221)
Pain (215)
What Other Drugs Cause Hormone-refractory prostate cancer?
LEUPROLIDE (180)
DOCETAXEL (123)
ENZALUTAMIDE (120)
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (110)
DAROLUTAMIDE (104)
ABIRATERONE (83)
PREDNISONE (58)
CABAZITAXEL (57)
BICALUTAMIDE (50)
CARBOPLATIN (27)
Which RADIUM RA-223 DICHLORIDE Alternatives Have Lower Hormone-refractory prostate cancer Risk?
RADIUM RA-223 DICHLORIDE vs RALOXIFENE
RADIUM RA-223 DICHLORIDE vs RALTEGRAVIR
RADIUM RA-223 DICHLORIDE vs RALTITREXED
RADIUM RA-223 DICHLORIDE vs RAMELTEON
RADIUM RA-223 DICHLORIDE vs RAMIPRIL